Salud financiera de hoja de balance de Torrent Pharmaceuticals
Salud financiera controles de criterios 5/6
Torrent Pharmaceuticals tiene un patrimonio de accionistas total de ₹67.1B y una deuda total de ₹44.9B, lo que sitúa su ratio deuda-patrimonio en 66.9%. Sus activos y pasivos totales son ₹147.4B y ₹80.4B respectivamente. El BAIT de Torrent Pharmaceuticals es de ₹24.2B, por lo que su ratio de cobertura de intereses es de 6.6. Tiene efectivo e inversiones a corto plazo que ascienden a ₹7.9B.
Información clave
57.7%
Ratio deuda-patrimonio
₹39.55b
Deuda
| Ratio de cobertura de intereses | 7.5x |
| Efectivo | ₹10.04b |
| Patrimonio | ₹68.56b |
| Total pasivo | ₹82.04b |
| Activos totales | ₹150.61b |
Actualizaciones recientes sobre salud financiera
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹52.9B) de TORNTPHARM superan a sus pasivos a corto plazo (₹49.0B).
Pasivo a largo plazo: Los activos a corto plazo de TORNTPHARM (₹52.9B) superan a sus pasivos a largo plazo (₹31.4B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de TORNTPHARM (55.2%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de TORNTPHARM ha pasado de 120.3% a 66.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de TORNTPHARM está bien cubierta por el flujo de caja operativo (63.9%).
Cobertura de intereses: Los pagos de intereses de la deuda de TORNTPHARM están bien cubiertos por el BAIT (6.6x cobertura).